BCL2L11, BCL2 like 11, 10018

N. diseases: 173; N. variants: 16
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.050 Biomarker disease BEFREE <i>In vitro</i> transfection of anti-tumor miR-101 induces BIM, a pro-apoptotic protein, expression in acute myeloid leukemia (AML). 29333128 2017
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.100 Biomarker disease BEFREE <i>In vivo</i>, erlotinib suppressed growth of BIM wide-type NSCLC cell xenographs by inducing apoptosis. 29312548 2017
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.100 GeneticVariation disease BEFREE 10 published and 3 unpublished studies that reported survival outcomes in NSCLC patients stratified according to BIM deletion were identified from PubMed and Embase. 28467813 2017
CUI: C1841972
Disease: Glucocorticoid Receptor Deficiency
Glucocorticoid Receptor Deficiency 		0.020 AlteredExpression disease BEFREE Glucocorticoid resistance in ALL xenografts was consistently associated with failure to up-regulate BIM expression after dexamethasone exposure despite confirmation of a functional glucocorticoid receptor. 20647567 2010
CUI: C0020097
Disease: HTLV-I Infections
HTLV-I Infections 		0.010 AlteredExpression group BEFREE HTLV-1 infection of human T cells also reduced their levels of Bim protein, and restoring Bim expression in HTLV-1-infected cells reduced their proliferation by inducing apoptosis. 25175936 2014
CUI: C1860707
Disease: TUBEROUS SCLEROSIS 2 (disorder)
TUBEROUS SCLEROSIS 2 (disorder) 		0.010 Biomarker disease BEFREE TSC2 phosphorylation at Ser664 (an ERK-dependent phosphorylation site) was prevented with U0126, and BIM-I treatment blocked PMA-induced phosphorylation of TSC2 at multiple residues (Ser664, Ser939, and Thr1462). 28286738 2017
CUI: C1841972
Disease: Glucocorticoid Receptor Deficiency
Glucocorticoid Receptor Deficiency 		0.020 Biomarker disease BEFREE Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. 30537507 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE BIM 26182 and BIM 26189 injected at the doses of 50 micrograms twice a day (s.c.) around the tumor for 10 to 21 days delayed the growth of SCLC 41 and of SCLC 75. 1325285 1992
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.040 Biomarker disease BEFREE BIM 26182 and BIM 26189 injected at the doses of 50 micrograms twice a day (s.c.) around the tumor for 10 to 21 days delayed the growth of SCLC 41 and of SCLC 75. 1325285 1992
CUI: C0001430
Disease: Adenoma
Adenoma 		0.040 Biomarker group BEFREE BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion. 16216913 2005
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.100 Biomarker disease BEFREE BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. 17973572 2007
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.100 Biomarker disease BEFREE BIM is induced by lung cancer cell lines that are sensitive to erlotinib but not by those resistant. 18089817 2007
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.100 Biomarker disease BEFREE BIM is induced by lung cancer cell lines that are sensitive to erlotinib but not by those resistant. 18089817 2007
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.100 Biomarker disease BEFREE BIM is induced by lung cancer cell lines that are sensitive to erlotinib but not by those resistant. 18089817 2007
CUI: C0338078
Disease: Non-Functioning Pituitary Gland Neoplasm
Non-Functioning Pituitary Gland Neoplasm 		0.010 GeneticVariation disease BEFREE BIM-23A760, a molecule with high affinity for D2R and sstr2, significantly inhibited [3H]thymidine incorporation in 23 out of 38 (60%) NFPA cultures (EC50=1.2 pM and Emax=-33.6+/-3.7%). 18509006 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. 18509006 2008
CUI: C0001430
Disease: Adenoma
Adenoma 		0.040 Biomarker group BEFREE BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. 18509006 2008
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.040 GeneticVariation disease BEFREE BIM is de-phosphorylated and upregulated following MEK1/2 inhibition in all CRC cell lines studied and knockdown of BIM reduces cell death, indicating that repression of BIM is a major part of the ability of BRAF(V600E) to confer growth factor-independent survival. 18806830 2008
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. 22145099 2011
CUI: C0023473
Disease: Myeloid Leukemia, Chronic
Myeloid Leukemia, Chronic 		0.090 Biomarker disease BEFREE BIM coding sequence analysis was performed in 72 imatinib-treated CML patients from a French population of our centre and in 29 healthy controls (reference population) as a case-control study. 24223824 2013
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.100 Biomarker disease BEFREE BCL2L11 mRNA expression is a biomarker of survival in EGFR-mutant NSCLC and can potentially be used for synthetic lethality therapies. 24493829 2014
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.010 AlteredExpression disease BEFREE BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. 24561519 2014
CUI: C0220597
Disease: Adult Hodgkin Lymphoma
Adult Hodgkin Lymphoma 		0.010 AlteredExpression disease BEFREE BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. 24561519 2014
CUI: C0220644
Disease: Childhood Hodgkin Lymphoma
Childhood Hodgkin Lymphoma 		0.010 AlteredExpression disease BEFREE BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. 24561519 2014
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 GeneticVariation phenotype BEFREE BIM deletion polymorphism may be involved in the tumorigenesis of the early-onset breast cancer among East Asians. 25909194 2015